Thiomuscimol
Thiomuscimol, also known as 5-aminomethyl-3-isothiazol, is a synthetic GABAA receptor agonist which is structurally related to the naturally occurring GABAA receptor agonist muscimol. It is approximately equipotent with muscimol as a GABAA receptor agonist in vitro. Unlike muscimol however, thiomuscimol does not to any extent additionally act as a GABA reuptake inhibitor. On the other hand, like muscimol, it is a substrate for and metabolized by GABA transaminase, which is said to have limited its usefulness and application in animal behavioral studies. The drug was first described in the scientific literature by Povl Krogsgaard-Larsen and colleagues by 1976. It was encountered as a novel designer drug online in 2024.